Navigation Links
NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. (Privately Held) today announced that Chief Executive Officer Dr. Allan E. Rubenstein will be presenting at two industry conferences during the month of September. The first presentation will take place on September 11th, 2009 at 11:40am as part of the Rodman & Renshaw 11th Annual Healthcare Conference in New York, New York. The second presentation will take place on September 23, 2009 at 4:15pm as part of the Life Sciences Summit 2009 in Hauppauge, New York. All times are local time.

Dr. Rubenstein will be presenting an overview of the Company's preclinical results related to its series of heat shock protein 90 (Hsp90) inhibitors, speak about the Company's forward drug development strategy and timeline, and present high-level fiscal results for 2009.

About NexGenix: NexGenix Pharmaceuticals Holdings, Inc. is a privately-held biotechnology company based in New York City. The Company's portfolio consists of a series of Hsp90 inhibitors, a novel target therapy for oncology and neurodegenerative disorders, which has attracted an enormous amount of development interest in the past several years. The Company's proprietary Hsp90 screening platform has already generated over 300 potential compounds. From this group, three lead drug candidates have been identified on the basis of superior efficacy, safety, and the ability to cross the blood brain barrier. The product profiles lend themselves to address diseases such as glioblastoma (or "glioma", commonly known as malignant brain tumor) and other cancers, as well as neurodegenerative disorders including the motor neuron disease ALS (Lou Gehrig's disease) and Parkinson's disease. Each of these indications represents a world-wide market of at least $1B/year. In addition, the Company has a clinical stage intralesional treatment for dermal neurofibromas, the most common lesion in Neurofibromatosis Type 1, and a research stage program in inhibitors of p21-activated kinase for indications including Neurofibromatosis Type 2, and Autism Spectrum Disorders.


'/>"/>
SOURCE NexGenix Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
3. ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
4. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
5. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
6. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
7. Rib-X Pharmaceuticals to Present at the 49th ICAAC
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
9. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
10. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
11. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):